#21 Harnessing the power of antibody-drug conjugates: How the Signal's Research Suite advances multi-modal drug development (On Demand)

Antibody-drug conjugates (ADCs) have emerged as an important class of targeted therapeutics, combining the targeting specificity of antibodies with the potency of cytotoxic drugs. Recent advances in ADC research have led to improved stability, efficacy, and safety. There is a clear trend within Antibody therapeutics towards ADCs with the improvement of novel technologies to address a growing cancer population worldwide. However, developing effective ADCs is expensive and poses unique informatics challenges. Researchers must integrate data across multiple modalities - from antibody discovery and engineering to small molecule payload development and optimization. Seamless collaboration between immunologists, protein engineers, chemists, and pharmacologists are essential. The Signals™ Research Suite is the first integrated informatics platform purpose-built to accelerate multi-modal drug development like ADCs and is composed of a trio of scientific software applications: 

  • Signals™ Notebook: The premier cloud-based electronic lab notebook that facilitates creation and communication about molecules of interest via hierarchical editing language for macromolecules (HELM), powered Chemdraw®.    
  • Signals™ VitroVivo: For data analysis, visualization, and curve fitting bioassay results for standardized and consistent results, powered by Spotfire®.  
  • Signals™ Inventa: Enabling multi-assay or multi-study comparison, powered by Spotfire, with the ability to find the best candidate to move forward, accelerating decision making. Researchers gain better visibility into ADC candidate profiling and can quickly determine structure-activity and structure-property relationships across modalities to select optimal conjugation sites and pairings. 

Attendees will gain insights into the latest trends and challenges in ADC development, informed by recent research and advancements in the field. The presentation will also emphasize the importance of integrating various data types and sources in the ADC development process, showcasing how the Signals Research Suite facilitates this integration, thereby driving more efficient, safer drug development. 

 

By submitting my personal data, I acknowledge that Revvity, Inc. and its affiliates ("Company") will process my personal data provided above consistent with the Company's Privacy Policy (available here).

Seminar Information
Date Presented:
March 27, 2024 11:00 AM Eastern
Length:
1 hour
Register Now
In order to access this program after registering, a TAS account will be provided for you based on the information you have entered.

To access your account after your purchase, use the My Account links on the left hand side of this page to login using the information your provide here.
According to our records there is already a TAS account using the email address you have provided.

To continue with your registration please enter your account password. If you do not know your account password you can retrieve it here: Forgot Password?
First Name:
Last Name:
Email:
Confirm Email:
Organization:
Country:
Product:
On-Demand
The email address you have entered has an existing TAS account.

Please enter your password in the field below. Forgot Password?

Email:
Password:
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Harnessing the Power of Antibody Drug Conjugates: How the Signal\'s Research Suite Advances Multi-Modal Drug Development

Antibody-drug conjugates (ADCs) have emerged as an important class of targeted therapeutics, combining the targeting specificity of antibodies with the potency of cytotoxic drugs. Recent advances in ADC research have led to improved stability, efficacy, and safety (Xu et al., 2023). There is a clear trend within Antibody therapeutics towards ADCs with the improvement of novel technologies to address a growing cancer population worldwide (Data Bridge Market Research, 2023). However, developing effective ADCs is expensive and poses unique informatics challenges. Researchers must integrate data across multiple modalities - from antibody discovery and engineering to small molecule payload development and optimization. Seamless collaboration between immunologists, protein engineers, chemists, and pharmacologists are essential. 

The Signals™ Research Suite is the first integrated informatics platform purpose-built to accelerate multi-modal drug development like ADCs and is composed of a trio of scientific software applications: 

  • Signals™ Notebook: The premier cloud-based electronic lab notebook that facilitates creation and communication about molecules of interest via hierarchical editing language for macromolecules (HELM), powered Chemdraw®.    
  • Signals™ VitroVivo: For data analysis, visualization, and curve fitting bioassay results for standardized and consistent results, powered by Spotfire®.  
  • Signals™ Inventa: Enabling multi-assay or multi-study comparison, powered by Spotfire, with the ability to find the best candidate to move forward, accelerating decision making. Researchers gain better visibility into ADC candidate profiling and can quickly determine structure-activity and structure-property relationships across modalities to select optimal conjugation sites and pairings. 

Attendees will gain insights into the latest trends and challenges in ADC development, informed by recent research and advancements in the field. The presentation will also emphasize the importance of integrating various data types and sources in the ADC development process, showcasing how the Signals Research Suite facilitates this integration, thereby driving more efficient, safer drug development. 

Speaker Information
Zev Wisotsky  [ view bio ]
ProductAddPrice
On-Demand
TAS Price:$0.00
Individual topic purchase: Selected